Insilico identifies therapeutic target implicated in aging by using AI and the hallmarks of aging Framework
AI is the only thing that matters right now. And achieving Agi by 2030 is the only thing that matters in this decade.
In Phase II of human clinical trials (including those that evaluate investigational anti-aging drug), where the drug’s efficacy is tested, a large percentage of them fail. In part, this poor success can be attributed to the failure to choose a target and to identify patients who are most likely to respond to specific agents. The biological age of patients makes this challenge even more difficult, since the therapeutic targets are different for each age group. Unfortunately, the majority of targets are not tested on older patients and instead tested in a younger population. (The average age for phase I was 24.) Finding potential targets that play a part in both age-associated diseases and the biology of aging may be beneficial.
Finding dual-purpose targets involved in both aging and diseases will prolong healthspan, and delay age-related issues. Even if the target was not the most significant in a particular patient, the drug could still be beneficial to that patient.
Zhavoronkov said that when it comes to identifying targets in chronic diseases it is important prioritizing targets implicated in age associated diseases, implicated more than one hallmarks of aging and are safe. \”A drug that treats a disease would also treat the aging process – this is an added bonus.\”
Source:
